Evidence map›Paper›PMID 31315927›Full record

ArticleThe Journal of biological chemistry2019

TIMAP inhibits endothelial myosin light chain phosphatase by competing with MYPT1 for the catalytic protein phosphatase 1 subunit PP1cβ.

Xin Wang, Marya Obeidat, Laiji Li, Phuwadet Pasarj, Salah Aburahess, Charles F B Holmes, Barbara J Ballermann

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xin WangDepartment of Medicine, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.
Marya ObeidatDepartment of Medicine, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.
Laiji LiDepartment of Medicine, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.
Phuwadet PasarjDepartment of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.
Salah AburahessDepartment of Medicine, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.
Charles F B HolmesDepartment of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2G3, Canada.
Barbara J BallermannDepartment of Medicine, University of Alberta, Edmonton, Alberta T6G 2G3, Canada. Electronic address: barbara.ballermann@ualberta.ca.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transforming growth factor-β membrane associated protein (TIMAP) is an endothelial cell (EC)-predominant PP1 regulatory subunit and a member of the myosin phosphatase target (MYPT) protein family. The MYPTs preferentially bind the catalytic protein phosphatase 1 subunit PP1cβ, forming myosin phosphatase holoenzymes. We investigated whether TIMAP/PP1cβ could also function as a myosin phosphatase. Endogenous PP1cβ, myosin light chain 2 (MLC2), and myosin IIA heavy chain coimmunoprecipitated from EC lysates with endogenous TIMAP, and endogenous MLC2 colocalized with TIMAP in EC projections. Purified recombinant GST-TIMAP interacted directly with purified recombinant His-MLC2. However, TIMAP overexpression in EC enhanced MLC2 phosphorylation, an effect not observed with a TIMAP mutant that does not bind PP1cβ. Conversely, MLC2 phosphorylation was reduced in lung lysates from TIMAP-deficient mice and upon silencing of endogenous TIMAP expression in ECs. Ectopically expressed TIMAP slowed the rate of MLC2 dephosphorylation, an effect requiring TIMAP-PP1cβ interaction. The association of MYPT1 with PP1cβ was profoundly reduced in the presence of excess TIMAP, leading to proteasomal MYPT1 degradation. In the absence of TIMAP, MYPT1-associated PP1cβ readily bound immobilized microcystin-LR, an active-site inhibitor of PP1c. By contrast, TIMAP-associated PP1cβ did not interact with microcystin-LR, indicating that the active site of PP1cβ is blocked when it is bound to TIMAP. Thus, TIMAP inhibits myosin phosphatase activity in ECs by competing with MYPT1 for PP1cβ and blocking the PP1cβ active site.

Indexed as

AnimalsBiocatalysisCell LineEndothelial CellsHumansMembrane ProteinsMiceMice, Inbred C57BLMyosin-Light-Chain PhosphataseProtein Phosphatase 1Membrane ProteinsMyosin-Light-Chain PhosphatasePPP1R12A protein, humanPPP1R16B protein, humanProtein Phosphatase 1angiogenesisendothelial cellinhibitormicrocystinmyosinmyosin phosphataseMYPT1phosphoprotein phosphatase 1 (PP1)

Identifiers

PMID31315927
PMCPMC6737228
OpenAlexW2961899111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.